The estimated Net Worth of Lori Anne Kunkel is at least $9.01 Миллион dollars as of 3 June 2024. Lori Kunkel owns over 20,500 units of Curis Inc stock worth over $104,550 and over the last 8 years he sold CRIS stock worth over $8,910,281. In addition, he makes $0 as Independent Director at Curis Inc.
Lori has made over 7 trades of the Curis Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he exercised 20,500 units of CRIS stock worth $76,875 on 3 June 2024.
The largest trade he's ever made was selling 39,232 units of Curis Inc stock on 14 June 2018 worth over $7,055,091. On average, Lori trades about 3,016 units every 75 days since 2016. As of 3 June 2024 he still owns at least 20,500 units of Curis Inc stock.
You can see the complete history of Lori Kunkel stock trades at the bottom of the page.
Dr. Lori A. Kunkel M.D. serves as Independent Director of the Company. Dr. Kunkel currently serves on the Board of Directors at Loxo Oncology, where she was formerly Acting Chief Medical Officer. Prior to Loxo Oncology, Dr. Kunkel served as Chief Medical Officer at Pharmacyclics, Inc. leading integrated clinical development highlighted by the approval of IMBRUVICA. She has also served as Chief Medical Officer at Proteolix Inc. (acquired by Onyx), Syndax, and ACT Biotech. Dr. Kunkel currently serves on the Board of Directors at Loxo Oncology, where she was formerly Acting Chief Medical Officer. Prior to Loxo Oncology, Dr. Kunkel served as Chief Medical Officer at Pharmacyclics, Inc. leading integrated clinical development highlighted by the approval of IMBRUVICA. She has also served as Chief Medical Officer at Proteolix Inc. (acquired by Onyx), Syndax, and ACT Biotech.
Lori Kunkel is 62, he's been the Independent Director of Curis Inc since 2016. There are 3 older and 6 younger executives at Curis Inc. The oldest executive at Curis Inc is Martyn Greenacre, 78, who is the Independent Chairman of the Board.
Lori's mailing address filed with the SEC is C/O NURIX THERAPEUTICS, INC., 1700 OWENS STREET, SUITE 205, SAN FRANCISCO, CA, 94158.
Over the last 24 years, insiders at Curis Inc have traded over $10,321,234 worth of Curis Inc stock and bought 10,678,594 units worth $25,596,192 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Discovery Technologies Ltd ... и James R Mcnab. On average, Curis Inc executives and independent directors trade stock every 62 days with the average trade being worth of $811,553. The most recent stock trade was executed by James E Dentzer on 27 January 2022, trading 5,500 units of CRIS stock currently worth $17,160.
curis is a publicly-traded biotechnology company (nasdaq: cris) focused on the development and commercialization of innovative drug candidates for the treatment of human cancers. curis’s pipeline of drug candidates includes cudc-907, which is currently being investigating in clinical trials in patients with relapsed or refractory diffuse large b-cell lymphoma with alterations in the myc oncogene. curis is also engaged in a broad collaboration with aurigene in the areas of immuno-oncology and precision oncology. as part of this collaboration, curis has exclusive licenses to oral small molecule antagonists of the pd1 and vista pathways, including pdl1/vista antagonist ca-170, and oral small molecule antagonists of the pd1 and tim3 pathways, including pdl1/tim3 antagonist ca-327, as well as to molecules designed to inhibit the irak4 kinase, including ca-4948. ca-170 is currently undergoing testing in a phase 1 trial in patients with advanced solid tumors and lymphomas. ca-4948 is currentl
Curis Inc executives and other stock owners filed with the SEC include: